A study of acoramidis for people with transthyretin amyloid cardiomyopathy
Treatments studied
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), either the inherited or non-inherited form.
- You must be about to start treatment with acoramidis as prescribed by your doctor.
- You must not have previously taken any disease-modifying treatment for ATTR-CM, such as tafamidis or gene-silencing therapies.
- You must not be currently participating in any other investigational drug or device study.
- You must not be under legal guardianship or any court-ordered protection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
This study looks at the long-term safety of the study drug acoramidis for people living with a heart condition called ATTR-CM. It may help doctors understand the long-term effects and benefits of this treatment.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
Hear when a new Transthyretin Amyloid Cardiomyopathy (ATTR-CM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.